FLUDEOXYGLUCOSE F18 Drug Patent Profile
When do Fludeoxyglucose F18 patents expire, and when can generic versions of Fludeoxyglucose F18 launch?
Fludeoxyglucose F18 is a drug marketed by Downstate Clincl, 3d Imaging Drug, Bamf, Barbara Ann Karmanos, Biomedcl Res Fdn, Brigham Womens, Cardinal Health 414, Essential Isotopes, Feinstein, Hot Shots Nm Llc, Isologic Innovative, Jubilant Draximage, Kettering Medctr, Kreitchman Pet Ctr, Ma General Hosp, Mcprf, Mem Sloan-kettering, Methodist Hosp Res, Midwest Medcl, Mips Crf, Ncm Usa Bronx Llc, Northland, Nukemed, Petnet, Pharmalogic, Pharmalogic Hldgs, Precision Nuclear, Queen Hamamatsu Pet, Sofie, Trustees Univ Pa, Ucla Biomedical, Ucsf Rodiopharm, Uihc Pet Imaging, Univ Michigan, Univ Southern Ca, Univ Tx Md Anderson, Univ Tx Sw Medctr, Univ Utah Cyclotron, Weill Medcl Coll, Wisconsin, and Wusm Cyclotron. and is included in forty-four NDAs.
The generic ingredient in FLUDEOXYGLUCOSE F18 is fludeoxyglucose f-18. There is one drug master file entry for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the fludeoxyglucose f-18 profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for FLUDEOXYGLUCOSE F18?
- What are the global sales for FLUDEOXYGLUCOSE F18?
- What is Average Wholesale Price for FLUDEOXYGLUCOSE F18?
Summary for FLUDEOXYGLUCOSE F18
| US Patents: | 0 |
| Applicants: | 41 |
| NDAs: | 44 |
| Finished Product Suppliers / Packagers: | 25 |
| Raw Ingredient (Bulk) Api Vendors: | 13 |
| Clinical Trials: | 198 |
| Patent Applications: | 335 |
| What excipients (inactive ingredients) are in FLUDEOXYGLUCOSE F18? | FLUDEOXYGLUCOSE F18 excipients list |
| DailyMed Link: | FLUDEOXYGLUCOSE F18 at DailyMed |
Recent Clinical Trials for FLUDEOXYGLUCOSE F18
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | PHASE1 |
| City of Hope Medical Center | PHASE1 |
| University of Washington | PHASE2 |
Pharmacology for FLUDEOXYGLUCOSE F18
| Drug Class | Radioactive Diagnostic Agent |
| Mechanism of Action | Radiopharmaceutical Activity |
US Patents and Regulatory Information for FLUDEOXYGLUCOSE F18
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univ Southern Ca | FLUDEOXYGLUCOSE F18 | fludeoxyglucose f-18 | INJECTABLE;INTRAVENOUS | 209341-001 | Dec 16, 2020 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Queen Hamamatsu Pet | FLUDEOXYGLUCOSE F18 | fludeoxyglucose f-18 | INJECTABLE;INTRAVENOUS | 203771-001 | Aug 31, 2015 | AP | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Univ Utah Cyclotron | FLUDEOXYGLUCOSE F18 | fludeoxyglucose f-18 | INJECTABLE;INTRAVENOUS | 204498-001 | Jun 23, 2015 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Petnet | FLUDEOXYGLUCOSE F18 | fludeoxyglucose f-18 | INJECTABLE;INTRAVENOUS | 079086-001 | Feb 25, 2011 | AP | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
